Cardiac involvement in pediatric hemolytic uremic syndrome.
Children
Hemolytic uremic syndrome
Myocardial dysfunction
Myocarditis
Risk factor
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
07
06
2021
accepted:
14
12
2021
revised:
14
12
2021
pubmed:
15
3
2022
medline:
26
10
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
Cardiac involvement is a known but rare complication of pediatric hemolytic uremic syndrome (HUS). We conducted a nationwide observational, retrospective case-control study describing factors associated with the occurrence of myocarditis among HUS patients. Cases were defined as hospitalized children affected by any form of HUS with co-existent myocarditis in 8 French Pediatric Intensive Care Units (PICU) between January 2007 and December 2018. Control subjects were children, consecutively admitted with any form of HUS without coexistent myocarditis, at a single PICU in Lyon, France, during the same time period. A total of 20 cases of myocarditis were reported among 8 PICUs, with a mean age of 34.3 ± 31.9 months; 66 controls were identified. There were no differences between the two groups concerning the season and the typical, Shiga toxin-producing Escherichia coli (STEC-HUS), or atypical HUS (aHUS). Maximal leukocyte count was higher in the myocarditis group (29.1 ± 16.3G/L versus 21.0 ± 9.9G/L, p = 0.04). The median time between admission and first cardiac symptoms was of 3 days (range 0-19 days), and 4 patients displayed myocarditis at admission. The fatality rate in the myocarditis group was higher than in the control group (40.0% versus 1.5%, p < 0.001). Thirteen (65%) children from the myocarditis group received platelet transfusion compared to 19 (29%) in the control group (p = 0.03). Our study confirms that myocarditis is potentially lethal and identifies higher leukocyte count and platelet transfusion as possible risk factors of myocarditis. A higher resolution version of the Graphical abstract is available as Supplementary information.
Sections du résumé
BACKGROUND
Cardiac involvement is a known but rare complication of pediatric hemolytic uremic syndrome (HUS). We conducted a nationwide observational, retrospective case-control study describing factors associated with the occurrence of myocarditis among HUS patients.
METHODS
Cases were defined as hospitalized children affected by any form of HUS with co-existent myocarditis in 8 French Pediatric Intensive Care Units (PICU) between January 2007 and December 2018. Control subjects were children, consecutively admitted with any form of HUS without coexistent myocarditis, at a single PICU in Lyon, France, during the same time period.
RESULTS
A total of 20 cases of myocarditis were reported among 8 PICUs, with a mean age of 34.3 ± 31.9 months; 66 controls were identified. There were no differences between the two groups concerning the season and the typical, Shiga toxin-producing Escherichia coli (STEC-HUS), or atypical HUS (aHUS). Maximal leukocyte count was higher in the myocarditis group (29.1 ± 16.3G/L versus 21.0 ± 9.9G/L, p = 0.04). The median time between admission and first cardiac symptoms was of 3 days (range 0-19 days), and 4 patients displayed myocarditis at admission. The fatality rate in the myocarditis group was higher than in the control group (40.0% versus 1.5%, p < 0.001). Thirteen (65%) children from the myocarditis group received platelet transfusion compared to 19 (29%) in the control group (p = 0.03).
CONCLUSION
Our study confirms that myocarditis is potentially lethal and identifies higher leukocyte count and platelet transfusion as possible risk factors of myocarditis. A higher resolution version of the Graphical abstract is available as Supplementary information.
Identifiants
pubmed: 35286451
doi: 10.1007/s00467-022-05427-2
pii: 10.1007/s00467-022-05427-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3215-3221Informations de copyright
© 2022. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Mody RK, Gu W, Griffin PM, Jones TF, Rounds J, Shiferaw B et al (2015) Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr 166:1022–1029
doi: 10.1016/j.jpeds.2014.12.064
Oakes RS, Siegler RL, McReynolds MA, Pysher T, Pavia AT (2006) Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 117:1656–1662
doi: 10.1542/peds.2005-0785
Sanders E, Brown CC, Blaszak RT, Crawford B, Prodhan P (2021) Cardiac Manifestation among Children with Hemolytic Uremic Syndrome. J Pediatr 235:144-148.e4. https://doi.org/10.1016/j.jpeds.2021.03.067
doi: 10.1016/j.jpeds.2021.03.067
pubmed: 33819463
pmcid: 8316308
Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey M-A, Ngo S et al (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554–562
doi: 10.2215/CJN.04760512
Frémeaux-Bacchi V, Sellier-Leclerc A-L, Vieira-Martins P, Limou S, Kwon T, Lahoche A et al (2019) Complement gene variants and Shiga toxin–producing Escherichia coli–associated hemolytic uremic syndrome: retrospective genetic and clinical study. Clin J Am Soc Nephrol 14:364–377
doi: 10.2215/CJN.05830518
Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A et al (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15–39
doi: 10.1007/s00467-015-3076-8
Andersen RF, Bjerre JV, Povlsen JV, Veien M, Kamperis K, Rittig S (2017) HUS-induced cardiac and circulatory failure is reversible using cardiopulmonary bypass as rescue. Pediatr Nephrol 32:2155–2158
doi: 10.1007/s00467-017-3736-y
Cooper LT (2009) Myocarditis. N Engl J Med 360:1526–1538
doi: 10.1056/NEJMra0800028
Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ et al (1987) Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1:3–14
pubmed: 3455232
Abu-Arafeh I, Gray E, Youngson G, Auchterlonie I, Russell G (1995) Myocarditis and haemolytic uraemic syndrome. Arch Dis Child 72:46–47
doi: 10.1136/adc.72.1.46
Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ (2019) Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 34:2261–2277
doi: 10.1007/s00467-018-4091-3
Ardissino G, Daccò V, Testa S, Civitillo CF, Tel F, Possenti I et al (2015) Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome. Pediatr Nephrol 30:345–352
doi: 10.1007/s00467-014-2918-0
Cobeñas CJ, Bresso PS, Lombardi LL, Amoreo OR, Ruscasso JD, Spizzirri AP et al (2015) Relationship between red blood cell transfusion requirements and severity of renal disease during the acute stage of hemolytic uremic syndrome. Pediatr Nephrol 30:2115–2119
doi: 10.1007/s00467-015-3147-x
Beneke J, Sartison A, Kielstein JT, Haller H, Nitschke M, Kunzendorf U et al (2017) Clinical and Laboratory Consequences of Platelet Transfusion in Shiga Toxin-Mediated Hemolytic Uremic Syndrome. Transfus Med Rev 31:51–55
doi: 10.1016/j.tmrv.2016.06.004
Ardissino G, Tel F, Possenti I, Testa S, Consonni D, Paglialonga F et al (2016) Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome. Pediatrics 137(1):2153
doi: 10.1542/peds.2015-2153
Rigamonti D, Simonetti GD (2016) Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature. Eur J Pediatr 175:1927–1931
doi: 10.1007/s00431-016-2790-y
Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE (2013) Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 28:919–925
doi: 10.1007/s00467-013-2414-y
Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AAR (2015) Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 125:1470–1476
doi: 10.1182/blood-2014-10-605493
Wisotzkey BL, Soriano BD, Albers EL, Ferguson M, Buddhe S (2018) Diagnostic role of strain imaging in atypical myocarditis by echocardiography and cardiac MRI. Pediatr Radiol 48:835–842
doi: 10.1007/s00247-017-4061-0
Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34:2636–2648
doi: 10.1093/eurheartj/eht210
Rodriguez-Gonzalez M, Sanchez-Codez MI, Lubian-Gutierrez M, Castellano-Martinez A (2019) Clinical presentation and early predictors for poor outcomes in pediatric myocarditis: A retrospective study. World J Clin Cases 7:548–561
doi: 10.12998/wjcc.v7.i5.548
Di Filippo S (2016) Improving outcomes of acute myocarditis in children. Expert Rev Cardiovasc Ther 14:117–125
doi: 10.1586/14779072.2016.1114884
Weil BR, Andreoli SP, Billmire DF (2010) Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome. Pediatr Nephrol 25:1693–1698
doi: 10.1007/s00467-010-1530-1